Molefe Philisiwe Fortunate, Masamba Priscilla, Oyinloye Babatunji Emmanuel, Mbatha Londiwe Simphiwe, Meyer Mervin, Kappo Abidemi Paul
Biotechnology and Structural Biochemistry (BSB) Group, Department of Biochemistry and Microbiology, Faculty of Science and Agriculture, University of Zululand, KwaDlangezwa 3886, South Africa.
Department of Biochemistry, College of Sciences, Afe Babalola University, PMB 5454, Ado-Ekiti 360001, Nigeria.
Pharmaceuticals (Basel). 2018 Sep 28;11(4):93. doi: 10.3390/ph11040093.
Cancer and infectious diseases such as Ebola, HIV, tuberculosis, Zika, hepatitis, measles and human schistosomiasis are serious global health hazards. The increasing annual morbidities and mortalities of these diseases have been blamed on drug resistance and the inefficacy of available diagnostic tools, particularly those which are immunologically-based. Antibody-based tools rely solely on antibody production for diagnosis and for this reason they are the major cause of diagnostic delays. Unfortunately, the control of these diseases depends on early detection and administration of effective treatment therefore any diagnostic delay is a huge challenge to curbing these diseases. Hence, there is a need for alternative diagnostic tools, discovery and development of novel therapeutic agents. Studies have demonstrated that aptamers could potentially offer one of the best solutions to these problems. Aptamers are short sequences of either DNA or RNA molecules, which are identified in vitro through a SELEX process. They are sensitive and bind specifically to target molecules. Their promising features suggest they may serve as better diagnostic agents and can be used as drug carriers for therapeutic purposes. In this article, we review the applications of aptamers in the theranostics of cancer and some infectious diseases.
癌症以及诸如埃博拉、艾滋病毒、结核病、寨卡病毒、肝炎、麻疹和人类血吸虫病等传染病是严重的全球健康威胁。这些疾病逐年上升的发病率和死亡率归咎于耐药性以及现有诊断工具的无效性,尤其是那些基于免疫的诊断工具。基于抗体的工具完全依赖抗体产生来进行诊断,因此它们是诊断延迟的主要原因。不幸的是,这些疾病的控制依赖于早期检测和有效治疗的实施,所以任何诊断延迟都是遏制这些疾病的巨大挑战。因此,需要替代诊断工具,发现和开发新型治疗药物。研究表明,适体有可能为这些问题提供最佳解决方案之一。适体是DNA或RNA分子的短序列,通过指数富集的配体系统进化(SELEX)过程在体外鉴定。它们敏感且能特异性结合靶分子。其有前景的特性表明它们可能成为更好的诊断剂,并可作为治疗用途的药物载体。在本文中,我们综述了适体在癌症和一些传染病诊疗中的应用。